Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Everest Medicines Ltd. ( (HK:1952) ) has shared an announcement.
Everest Medicines has responded to the approval of a generic version of its kidney disease drug NEFECON in China by stressing that NEFECON remains protected under a valid Chinese patent until May 2029, with the patent duly registered on the national platform for marketed drugs. Citing China’s Patent Law and the rules governing early settlement of drug patent disputes, the company warned that any manufacture, sale, promotion or import of products infringing this patent before its expiry would constitute infringement, and reminded generic applicants who have pledged not to market before patent expiry that they must honor this commitment; Everest pledged to take lawful action against suspected violations while reiterating its broader stance that robust IP enforcement is critical to fair competition, sustained innovation and continued patient access to innovative therapies in China.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company focused on bringing breakthrough and innovative therapies to China to address urgent medical needs, particularly in specialty and rare diseases. The company emphasizes strong intellectual property protection as a foundation for sustaining pharmaceutical R&D innovation and ensuring long-term access to major innovative drugs in the Chinese market.
Average Trading Volume: 3,328,142
Technical Sentiment Signal: Hold
Current Market Cap: HK$15.78B
See more insights into 1952 stock on TipRanks’ Stock Analysis page.